TRThomas P. Roddy
Thomas P. Roddy
*This is an algorithmically generated author record based on publicly available information.
Research Subjects
Research Interests
Thomas P. Roddy has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Douglas G. Johns
MRL, Merck & Co., Inc., Rahway, NJ (D.G.J., L.-C.C., P.B., A.B., T.B., P.G.B., I.C., F.-X.D., R.M.G., E.D.G., Y.G., S.N.H., J.M.J., H.J., E.A.K., K.A.K., J.T.K., E.L., C.L.L., A.Y.H.L., L.L., A.G.N., E.A.O., S.A.S., D.A.T., T.J.T., P.V., K.v.D., D.G.W., A.X., T.Z., D.Z., S.Z., X.Z., H.J.Z., A.M.W., H.B.W.).
1 shared publication - Jose Castro-Perez
Departments of Analytical Biochemistry, Merck & Co., Inc., Kenilworth, NJ, USA
1 shared publication - Sheng-Ping Wang
Departments of Cardiovascular Diseases/Atherosclerosis, Merck & Co., Inc., Kenilworth, NJ, USA
1 shared publication - Stephen F. Previs
Merck Research Laboratories, Kenilworth, New Jersey
1 shared publication - Ying Chen
Departments of Cardiovascular Diseases/Atherosclerosis, Merck & Co., Inc., Kenilworth, NJ, USA
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 762, 256-262
Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: In vitro vs in vivo comparison using anacetrapib and dalcetrapib
- 1 September 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 762, 256-262
Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: In vitro vs in vivo comparison using anacetrapib and dalcetrapib